Update on the current revolution in cancer immunotherapy.
作者信息
Renrick Ariana Nicole, Dunbar Zerick Terrell, Shanker Anil
机构信息
Department of Biochemistry, Cancer Biology, Neuroscience & Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.
Department of Microbiology, Immunology & Physiology, School of Medicine, Meharry Medical College, Nashville, TN, USA.
出版信息
Immunotherapy. 2019 Jan;11(1):15-20. doi: 10.2217/imt-2018-0135.
PMID:30702010
Abstract
摘要
相似文献
1
Update on the current revolution in cancer immunotherapy.癌症免疫治疗当前变革的最新进展。
Immunotherapy. 2019 Jan;11(1):15-20. doi: 10.2217/imt-2018-0135.
2
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.人类癌症免疫疗法的“最终共同通路”：靶向随机体细胞突变
Nat Immunol. 2017 Feb 15;18(3):255-262. doi: 10.1038/ni.3682.
3
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.针对免疫检查点受体和分子的自然杀伤细胞治疗调节。
Front Immunol. 2018 Sep 10;9:2041. doi: 10.3389/fimmu.2018.02041. eCollection 2018.
4
Introduction: Cancer Immunology Special Issue-Immunotherapy.引言：癌症免疫学特刊——免疫疗法。
Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.
5
Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?新抗原异质性：免疫反应及对免疫检查点阻断敏感性的关键驱动因素？
Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064.
6
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.PD-L1 靶向高亲和力 NK（t-haNK）细胞可诱导直接抗肿瘤作用，并靶向抑制性 MDSC 群体。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2019-000450.
7
[Era of cancer immunotherapy has come].癌症免疫治疗时代已经来临。
Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):164-71. doi: 10.2177/jsci.39.164.
8
Coinhibitory Pathways in Immunotherapy for Cancer.癌症免疫治疗中的共抑制途径。
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
9
Toward in silico Identification of Tumor Neoantigens in Immunotherapy.在免疫治疗中进行肿瘤新抗原的计算机识别。
Trends Mol Med. 2019 Nov;25(11):980-992. doi: 10.1016/j.molmed.2019.08.001. Epub 2019 Sep 4.
10
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.TIGIT和CD96：癌症免疫治疗的新型检查点受体靶点
Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.
引用本文的文献
1
Tumor neoantigens as key drivers of significant anti - tumor immunity in triple - negative breast cancer mouse models.肿瘤新抗原作为三阴性乳腺癌小鼠模型中显著抗肿瘤免疫的关键驱动因素。
Neoplasia. 2025 Jul 8;67:101205. doi: 10.1016/j.neo.2025.101205.
2
Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.用于治疗乳腺癌的嵌合抗原受体T细胞（CAR-T）疗法的现状与创新进展
Cancer Cell Int. 2025 Jan 4;25(1):3. doi: 10.1186/s12935-024-03615-8.
3
Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.小分子免疫调节剂作为胶质母细胞瘤的下一代治疗药物
Cancers (Basel). 2024 Jan 19;16(2):435. doi: 10.3390/cancers16020435.
4
Extracellular K Dampens T Cell Functions: Implications for Immune Suppression in the Tumor Microenvironment.细胞外钾离子抑制T细胞功能：对肿瘤微环境中免疫抑制的影响
Bioelectricity. 2019 Sep 1;1(3):169-179. doi: 10.1089/bioe.2019.0016. Epub 2019 Sep 16.
5
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.度伐鲁单抗联合替西木单抗治疗实体瘤的系统评价。
Adv Ther. 2021 Jul;38(7):3674-3693. doi: 10.1007/s12325-021-01796-6. Epub 2021 Jun 8.
6
Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.硼替佐米通过诱导 miR-155 介导的 SOCS1 和 SHIP1 下调来维持 T 细胞功能。
Front Immunol. 2021 Feb 25;12:607044. doi: 10.3389/fimmu.2021.607044. eCollection 2021.
7
Critical Neurotransmitters in the Neuroimmune Network.神经免疫网络中的关键神经递质。
Front Immunol. 2020 Aug 21;11:1869. doi: 10.3389/fimmu.2020.01869. eCollection 2020.
8
Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.淋巴细胞特异性蛋白 1 表达水平升高参与胶质母细胞瘤中白细胞迁移和免疫抑制微环境的调节。
Aging (Albany NY). 2020 Jan 29;12(2):1656-1684. doi: 10.18632/aging.102706.
9
Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?多酚类化合物作为肿瘤微环境中的免疫调节化合物：是敌是友？
Int J Mol Sci. 2019 Apr 6;20(7):1714. doi: 10.3390/ijms20071714.
10
Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.树突状细胞表达的 Notch Delta-like 和 Jagged 配体在抗肿瘤 T 细胞免疫中的决定性作用。
J Immunother Cancer. 2019 Apr 2;7(1):95. doi: 10.1186/s40425-019-0566-4.
Zotero 插件